Project Grant R41EY036319
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $312K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbia, MO 65211, USA
Similar Awards
- The National Eye Institute (NEI), under the federal Vision Research grant program (CFDA 93.867), awarded a $300,016 project grant to Fannin Partners LLC, a Houston-based biomedical research company, to develop SCG3 raptamers as a novel targeted therapy for wet age-related macular degeneration (AMD). Wet AMD is a leading cause of vision loss, affecting over 1.25 million individuals in the United States. The project aims to create an aptamer-based treatment that targets secretogranin III (SCG3), a...
- The National Eye Institute (NEI), under its Vision Research federal grant program (CFDA 93.867), awarded a $431,750 Project Grant to the University of Houston System to develop a mutation-independent therapy for retinal degenerations caused by PRPH2 gene mutations. The two-year grant, awarded on August 1, 2025, aims to determine the applicability of a rhodopsin-specific antisense oligonucleotide (RHO-ASO) treatment to various PRPH2 mutation mouse models and investigate the efficacy of external...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $306,814 to Piximune, Inc. to develop an antibody-based, gene-agnostic treatment for inherited retinal degeneration, such as retinitis pigmentosa. The proposed approach aims to augment natural mechanisms that eliminate toxic cellular debris from dead and dying photoreceptor cells, thereby protecting surrounding functional cells and preventing secondary retinal damage independent of the causal...
- The National Eye Institute (NEI), under the Department of Health and Human Services, awarded a $358,065 Project Grant to Revel Pharmaceuticals Inc., a biotechnology company in San Francisco, California. The grant is part of the NEI's Vision Research program (CFDA 93.867), which supports research to understand, prevent, and treat vision-related conditions and diseases. The goal of this Phase I grant is for Revel Pharmaceuticals to optimize lead drug candidates and demonstrate the activity of...
- This $305,321 Project Grant awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports the clinical development and commercialization of a topical ophthalmic treatment for neovascular age-related macular degeneration (NAMD). The funding will enable the awardee, Neovascularx, Inc., to advance their AMD101 (rifampicin) compound, which aims to provide a less invasive, home-based alternative to the current standard of care intravitreous injections for...
- The National Eye Institute (NEI) awarded a $173,016 Project Grant to the Whitehead Institute for Biomedical Research to conduct research on identifying and characterizing novel oxidative protective genes that can prevent retinal pigment epithelium (RPE) degeneration, a key cause of age-related macular degeneration (AMD). The research project, titled "Systematic Identification and Mechanistic Characterization of Novel Oxidative Protective Genes to Prevent RPE Degeneration", aims to...
- The National Eye Institute (NEI), under the federal Vision Research grant program (CFDA 93.867), awarded a $431,750 Project Grant to the University of Louisville to study the role of neurexin proteins in retinal structure and function. The grant, effective from September 1, 2025 to August 31, 2027, aims to 1) determine the function of three neurexin genes and their isoform-specific expression patterns within the retina, and 2) characterize the cell-type-specific expression of neurexin isoforms...
- This Project Grant award of $310,952 from the National Eye Institute's Vision Research program, awarded on August 1, 2025, supports the development of a novel gene therapy approach by Bedrock Therapeutics, Inc., a small disadvantaged biotech company located in Raleigh, North Carolina. The goal is to create an effective and practical treatment for neovascular age-related macular degeneration (NAMD), the leading cause of blindness in people over 50. Bedrock's strategy combines an...
- This Project Grant award from the National Eye Institute (NEI), part of the U.S. Department of Health and Human Services, provides $385,000.00 in funding to Wayne State University to conduct research on genetic and glial support mechanisms in acute and chronic models of photoreceptor degeneration. The research aims to understand, prevent, and treat vision-related conditions and diseases, a focus area of NEI's Vision Research federal grant program (CFDA 93.867). The study will compare...
- This Project Grant award from the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) is funding research to develop an innovative gene therapy approach using self-amplifying and self-splicing RNA technologies. The $346,500 award, spanning September 2024 to September 2026, aims to evaluate the longevity, immunogenicity, and potential in vivo side effects of this novel mRNA-based therapy for treating inherited retinal dystrophies. The award recipient, The...